Core Viewpoint - The company, Metro Design (003013.SZ), has signed contracts with Guangzhou Metro Group for energy management projects related to the control systems of several metro lines, totaling 924 million yuan [1]. Group 1 - The company received contracts for the energy management projects for Line 1, the original Line 2, and the first section of Line 4 [1]. - The total value of the contracts is 924 million yuan, covering the period from 2025 to 2043 [1]. - The contracts are divided into two parts: Contract One for Operation Center One and Contract Two for Operation Center Two [1].

Core Viewpoint - The U.S. Department of Commerce announced the final ruling on anti-dumping and countervailing investigations regarding erythritol products originating from China, which significantly impacts the company's export conditions and market competitiveness [1] Summary by Category Anti-Dumping and Countervailing Duties - The company, as a mandatory respondent, faces a countervailing duty rate of 8.63% [1] - Other Chinese manufacturers/exporters are subject to countervailing duty rates ranging from 4.54% to 8.12% [1] - The company did not qualify for separate rates as an exporter, resulting in a unified anti-dumping tax rate of 184.26%, a reduction of 266.38% from the preliminary ruling of 450.64% [1] Export Conditions - When exporting through a specific separate rate channel (SRA), the company can apply an anti-dumping cash deposit rate of 84.95% [1] - The combined execution tax rate for exports to the U.S. through this specific channel is 93.58%, which includes the anti-dumping cash deposit rate and the countervailing duty rate [1] Market Impact - The high tax rate is expected to weaken the company's cost competitiveness in the U.S. market [1] - The company faces risks of reduced orders and loss of market share for the affected products due to these duties [1]

格隆汇2月9日丨电连技术(300679.SZ)公布，拟回购金额不低于人民币1亿元且不超过人民币2亿元，回 购股份的价格区间不超过人民币69.72元/股，本次回购股份将用于员工持股计划或股权激励，若公司未 能在本次股份回购实施结果暨股份变动公告日后三年内转让完毕已回购股份，尚未转让的回购股份将依 法予以注销。 ...

为保证董事会工作的正常进行，根据《公司法》等相关法律法规和《公司章程》的规定，经公司董事长 提名，董事会提名委员会任职资格审查，公司第十届董事会第六次临时会议审议通过了《关于聘任姜锋 先生为董事会秘书的议案》，同意聘任姜锋先生为公司董事会秘书，任期与公司第十届董事会任期相 同。姜锋先生已取得深圳证券交易所颁发的《董事会秘书资格证书》，具备履行职责所必须的专业知识 能力。 格隆汇2月9日丨仁和药业(000650.SZ)公布，公司董事会近日收到公司董事会秘书陈国锋先生的书面辞 职报告，陈国锋先生因个人原因，申请辞去公司董事会秘书职务。根据相关法律法规、规范性文件的有 关规定，陈国锋先生的辞职报告自送达董事会时生效。陈国锋先生原任期于2028年5月26日到期，未持 有公司股份，辞职后将不再担任公司任何职务。 ...

Core Viewpoint - The controlling shareholder of *ST Guohua (600636.SH), China Cultural Industry Development Group Co., Ltd., plans to increase its stake in the company by acquiring between 1% and 2% of the total share capital within 12 months from the announcement date [1] Group 1 - The announcement regarding the share acquisition plan was made on April 8, 2025 [1] - The controlling shareholder intends to use methods such as centralized bidding and block trading to purchase the shares [1] - As of February 8, 2026, the shareholder has already acquired 4.3865 million shares, which represents 1% of the company's total share capital [1]

格隆汇2月9日丨中国宝安(000009.SZ)公布，根据宁波杉杉股份（维权）有限公司于2026年2月9日披露 的《宁波杉杉股份有限公司关于控股股东及其子公司签署重整投资协议的公告》（公告编号：2026- 004），公司及所牵头的联合体未中选成为杉杉集团及其全资子公司宁波朋泽实质合并重整的重整投资 人。根据杉杉集团和宁波朋泽合并重整案管理人之文件规定，杉杉集团和宁波朋泽合并重整案管理人将 退返公司前期缴纳的尽调保证金。 ...

格隆汇2月9日丨新坐标(603040.SH)公布，公司董事会于近日收到独立董事张武翔先生递交的书面辞职 报告。张武翔先生因职务变动，根据高校合规要求，不能继续在企业兼职，为严格遵守相关规定，张武 翔先生申请辞去公司第六届董事会独立董事及薪酬与考核委员会成员的相关职务。辞去前述职务后，张 武翔先生将不再担任公司任何职务。 ...

Group 1 - The core point of the article is that Zhifei Biological Products Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its recombinant varicella-zoster virus vaccine (ZFA01) in individuals aged 40 and above [1] Group 2 - The clinical trial will focus on the prevention of shingles, indicating a strategic move into the vaccine market for older populations [1]

Core Viewpoint - The company,漫步者 (002351.SZ), has approved the transfer of its 1.5661% stake in 乐韵瑞 to two investment partnerships for a total of approximately 1,256.00 million yuan, which will not significantly impact its financial indicators for the year 2026 [1] Group 1 - The company will transfer its stake for 966.3823 million yuan to 南京五源兴致创业投资合伙企业 (Limited Partnership) [1] - The company will also transfer its stake for 966.3724 million yuan to 宁波甬元稳仲创业投资合伙企业 (Limited Partnership) [1] - The transactions have been reviewed and approved by the independent directors and do not constitute a related party transaction or a major asset restructuring as defined by the relevant regulations [1]

Core Viewpoint - Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of Zhongguancun (000931.SZ), has received approval from the National Medical Products Administration for its drug "Tramadol Hydrochloride Tablets" (specification: 50mg), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval signifies a key milestone for Beijing Huasu in the pharmaceutical market [1] - The drug "Tramadol Hydrochloride Tablets" is now positioned to compete effectively in the generic drug sector [1] - This development may enhance the company's revenue potential and market share in the pain management segment [1]